Alliance for Clinical trials in oncology Foundation
special projects allocation
 

 

 

 



The Alliance for Clinical Trials in Oncology Foundation (Alliance Foundation) announces a request for proposals to support research focused on addressing high priority research areas defined during the Alliance 2023 Scientific Strategic Retreat, which is held every two years. The goal of these priorities is to focus innovation by Alliance scientific committees on a few strategic areas, with the expectation that attention to these priorities will challenge researchers to move beyond what is currently possible and accelerate the development of new treatments, cancer control approaches, and cancer care delivery results. These strategic priorities generally focus upon fostering engagement of new disciplines or technologies relevant to Alliance research, or upon work to improve the design and implementation of Alliance clinical trials. 

Current Alliance Strategic Priorities were announced in January 2023:

  1. Eliminate burden at all levels (site, patient, NCTN) with operational efficiency, which could include streamlined protocols that have few key/strategic goals, review of protocol templates, coordination with NCTN partners.
  2. Scientific validation of streamlined data collection
  3. Use of annotated banked biospecimens and/or imaging to generate discovery using novel methods, which could include generation of pilot data leading to new Alliance funding/ discovery driven clinical research
  4. Efficiency in data collection and reduction of burden on sites through use of EHR for data transmissions or EHR based clinical research
  5. Leveraging ASTOR: infrastructure as potential resource for application and as a resource for broader scientific collaboration
  6. Novel study designs/ex: exploration of novel design EP to reduce study duration (i.e., ctDNA clearance at X timepoint)
  7. Improve inclusion and learnings/data collection on race/ethnicity and rural vs urban
  8. Utilize/develop/validate novel methods to support/inclusion of diverse populations in research   ex: telehealth, electronic personalized system, participant navigation

Proposal Due Date and Submission Information will be available in the coming week.
In the meantime, please direct questions to e-mail Awards@AllianceNCTN.org


Award Recipients
2022 | Alliance for Clinical Trials in Oncology Foundation Special Project Allocation

  • Proposal: "Fostering Diversity in Investigators and Accrual Within the Alliance"
    Marie E. Wood, MD, University of Colorado School of Medicine
    John P. Leonard, MD, Weill Cornell Medical College
    Aminah Jatoi, MD, Mayo Clinic
    Lucile L. Adams-Campbell, PhD, Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

  • Proposal: "Differential Effects of Social Disadvantage on Patient Outcomes in Gastrointestinal Clinical Trials"
    Rebecca A. Snyder, MD, MPH, FACS, FSSO, Brody School of Medicine at East Carolina University

  • Proposal: "The Alliance Participant Engagement Portal (PEP)"
    Suzanne George, MD, Alliance for Clinical Trials in Oncology

  • Proposal: "Enhancing SDMC Clinical Trial Infrastructure to Improve Efficiency and Consistency in Alliance Trials"
    Ann L. Oberg, MD, Alliance Computational Genomics and Bioinformatics

  • Proposal: "Value of De-escalation of Immunotherapy in Early Stage Triple-Negative Breast Cancer: OptimICE-pCR"
    Fabrice Smieliauskas, MD, Wayne State University
    Stephen Edge, MD, FACS, FASCO, Roswell Park Comprehensive Cancer Center

2018 | Alliance for Clinical Trials in Oncology Foundation Special Project Allocation

  • Alvaro J. Alencar, MD, University of Miami: "Health disparities in lymphoma: Analysis of a critical and often overlooked prognostic marker"
  • James L. Chen, MD, Ohio State University: "Alliance Harmonized and Unified Biodashboard (HUB) Initiative"
  • Wendy L. Frankel, MD, Ohio State University: "Automatic detection of tumor buds in colorectal cancer patients from H&E images"
  • Andrew Hantel, MD, Dana-Farber Cancer Institute: "Development and piloting of a novel provider feedback intervention to improve clinical trial and biobank enrolment diversity"
  • Maryam B. Lustberg, MD, MPH, Ohio State University: "PIN ALLIANCE: Power in numbers using harmonized GWAS and toxicity data"

2016 | Alliance for Clinical Trials in Oncology Foundation Special Project Allocation

  • Ya-Chen Tina Shih, PhD, University of Texas MD Anderson Cancer Center, and Tina W. F. Yen, MD, MS, Medical College of Wisconsin: "The effect of preoperative breast MRI on costs among women with breast cancer: an economic analysis of Alliance A011104"
  • Terrance M. Williams, MD, PhD, and David P. Carbone, MD, PhD, Ohio State University Comprehensive Cancer Center: "T cell receptor sequencing to predict responders and nonresponders to chemoradiation and atezolizumab for locally advanced non-small cell lung cancer"
  • Federico Innocenti, MD, PhD, and Naim Rashid, PhD, University of North Carolina-Chapel Hill: "Machine learning prognostic and predictive analyses for metastatic colorectal cancer – C80405"
  • Ellen M. Lavoie Smith, PhD, RN, FAAN, University of Michigan and David Zahrieh, PhD, Mayo Clinic: "Patient-targeted ePRO educational resource (ePRO-E) to increase ePRO uptake within Alliance clinical trials"
  • Sumithra Mandrekar, PhD, Mayo Clinic and David E. Kozono, MD, PhD, Brigham and Women’s Hospital: "Streamlining tumor response criteria using iRECIST in Alliance immune-oncology trials"